Influenza Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | AlloVir, Ansun Biopharma, MYMETICS, AVM Biotechnology, CELTRION, Cidara, Codagenix, Cocrystal, CureVac

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 120+ key pharma and biotech companies are working on 120+ pipeline drugs in the Influenza therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Influenza Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Influenza Therapeutics Market.

The report provides a detailed description of the Influenza drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the Influenza Clinical Trial Activities and Regulatory Developments in the domain @
https://www.delveinsight.com/report-store/influenza-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Influenza Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Influenza therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Influenza treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Influenza drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreements, and financing details for future advancement in the Influenza treatment market.

Learn More about the Clinical and Commercial Development Activities in the Influenza Therapeutics Domain @
https://www.delveinsight.com/report-store/influenza-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Influenza Therapeutics Analysis
There are approx. 120+ key companies developing therapies for Influenza. Currently, Moderna is leading the therapeutics market with its Influenza drug candidates in the most advanced stage of clinical development.

Influenza Companies in the Therapeutics Market Include:
Airway Therapeutics, Inc., AlloVir, Ansun Biopharma, Ansun Biopharma, AVM Biotechnology LLC, Avalia Immunotherapies, BlueWillow Biologics, CELTRION INC., Cidara Therapeutics, Inc., Clover Biopharmaceuticals, Codagenix, Cocrystal Pharma Inc, CSL Limited, CureVac AG, EMERGENT, Emergent BioSolutions, Emergex Vaccines, ENA Respiratory Pty Ltd, FluGen Inc, GlaxoSmithKline, Guangdong Raynovent Biotech Co., Ltd, Guangzhou Henovcom Bioscience, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Meiji Holdings Co., Ltd., Mitsubishi Chemical Group Corporation, Moderna, MYMETICS, Novavax, Osivax, Pfizer, Poolbeg Pharma, PrEP Biopharm, SAB Biotherapeutics, Sunshine Lake Pharma Co., Ltd., Vir Biotechnology, Viriom, and many others.

Emerging and Marketed Influenza Therapies Covered in the Report Include:
• mRNA-1010: Moderna
• SAB-176: SAB Biotherapeutics
• INNA-051: ENA Respiratory Pty Ltd
• CODA-VAX H1N1: Codagenix
• ALVR106: AlloVir
And Many More

Get an in-depth Assessment of the Emerging Therapies and Influenza Companies Actively Working in the Market @
https://www.delveinsight.com/sample-request/influenza-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

The Report Covers the Emerging Influenza Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates

Route of Administration
Influenza pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Molecule Type
Products have been categorized under various Molecule types such as
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Request for Sample PDF to Understand More About the Influenza Treatment Outlook and Future Perspectives @
https://www.delveinsight.com/sample-request/influenza-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Influenza Current Treatment Patterns
4. Influenza - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Influenza Late-Stage Products (Phase-III)
7. Influenza Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Influenza Discontinued Products
13. Influenza Product Profiles
14. Influenza Companies
15. Influenza Drugs
16. Dormant and Discontinued Products
17. Influenza Unmet Needs
18. Influenza Future Perspectives
19. Influenza Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings @
https://www.delveinsight.com/sample-request/influenza-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.